RU2009145054A - HUMAN OXYNTHOMODULIN, ITS APPLICATION, A MEDICINE ON ITS BASIS AND METHOD OF APPLICATION FOR THE TREATMENT AND PREVENTION OF HYPERGLYCEMIA - Google Patents
HUMAN OXYNTHOMODULIN, ITS APPLICATION, A MEDICINE ON ITS BASIS AND METHOD OF APPLICATION FOR THE TREATMENT AND PREVENTION OF HYPERGLYCEMIA Download PDFInfo
- Publication number
- RU2009145054A RU2009145054A RU2009145054/15A RU2009145054A RU2009145054A RU 2009145054 A RU2009145054 A RU 2009145054A RU 2009145054/15 A RU2009145054/15 A RU 2009145054/15A RU 2009145054 A RU2009145054 A RU 2009145054A RU 2009145054 A RU2009145054 A RU 2009145054A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- prevention
- hyperglycemia
- alpha
- sialic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
1. Оксинтомодулин человека, ковалентно связанный с гомополимерным полисахаридом, содержащим 50 звеньев альфа-2,8 сиаловой кислоты. ! 2. Лекарственный препарат для лечения или профилактики гипергликемии, содержащий в качестве активного вещества эффективное количество оксинтомодулина человека, ковалентно связанного с гомополимерным полисахаридом, содержащим 50 звеньев альфа-2,8 сиаловой кислоты, а также стабилизирующие добавки, смешанные с апирогенной водой или другими фармацевтически приемлимыми носителями. ! 3. Способ лечения и профилактики гипергликемии при сахарном диабете 2 типа у пациента, который нуждается в указанном лечении или профилактике, включающий подкожное введение лекарственного препарата, содержащего в качестве активного вещества оксинтомодулин человека, ковалентно связанный с гомополимерным полисахаридом, содержащим 50 звеньев альфа-2,8 сиаловой кислоты. ! 4. Применение оксинтомодулина человека, ковалентно связанного с гомополимерным полисахаридом, содержащим 50 звеньев альфа-2,8 сиаловой кислоты в качестве активного вещества лекарственного препарата для лечения и профилактики гипергликемии при сахарном диабете 2 типа. 1. Human oxyntomodulin covalently linked to a homopolymeric polysaccharide containing 50 alpha-2.8 sialic acid units. ! 2. A drug for the treatment or prevention of hyperglycemia, containing as an active substance an effective amount of human oxyntomodulin covalently bound to a homopolymer polysaccharide containing 50 alpha-2.8 sialic acid units, as well as stabilizing additives mixed with pyrogen-free water or other pharmaceutically acceptable carriers. ! 3. A method for the treatment and prevention of hyperglycemia in type 2 diabetes mellitus in a patient in need of said treatment or prevention, comprising subcutaneous administration of a drug containing human oxyntomodulin as an active substance covalently linked to a homopolymer polysaccharide containing 50 alpha-2 units, 8 sialic acid. ! 4. The use of human oxyntomodulin covalently linked to a homopolymer polysaccharide containing 50 units of alpha-2,8 sialic acid as an active substance of a drug for the treatment and prevention of hyperglycemia in type 2 diabetes mellitus.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009145054/15A RU2524204C2 (en) | 2009-11-30 | 2009-11-30 | Human oxyntomodulin, its application, medication based thereon and method of applying medication for treatment and prevention of hyperglycemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2009145054/15A RU2524204C2 (en) | 2009-11-30 | 2009-11-30 | Human oxyntomodulin, its application, medication based thereon and method of applying medication for treatment and prevention of hyperglycemia |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009145054A true RU2009145054A (en) | 2011-06-10 |
RU2524204C2 RU2524204C2 (en) | 2014-07-27 |
Family
ID=44736408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009145054/15A RU2524204C2 (en) | 2009-11-30 | 2009-11-30 | Human oxyntomodulin, its application, medication based thereon and method of applying medication for treatment and prevention of hyperglycemia |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2524204C2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2351776A1 (en) * | 2005-06-13 | 2011-08-03 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
EP2025684A1 (en) * | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
-
2009
- 2009-11-30 RU RU2009145054/15A patent/RU2524204C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2524204C2 (en) | 2014-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081254A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AVE0010 AND INSULIN GLARGINE | |
EA200501420A1 (en) | DELIVERY DEVICE FOR DRUG AND CELL THERAPY | |
EP2829265A3 (en) | Novel formulations for treatment of migraine | |
MX2013011174A (en) | Prevention of hypoglycaemia in diabetes mellitus type 2 patients. | |
AR099078A2 (en) | A MEDICINAL PRODUCT THAT INCLUDES ACETATO DE GLATIRAMER | |
CY1121822T1 (en) | EVENING INTRAVENTRICULAR ADMINISTRATION | |
RU2013114376A (en) | APPLICATION AVE0010 FOR THE PRODUCTION OF A MEDICINE FOR TREATMENT OF TYPE 2 DIABETES | |
EA201270144A1 (en) | COMBINED THERAPY FOR TREATMENT OF DIABETES | |
RS52629B (en) | Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes | |
RU2013123646A (en) | COMBINED COMPOSITION | |
MX2012000275A (en) | Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement. | |
RU2015116264A (en) | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN PATIENTS WITH DIABETES | |
US9549904B2 (en) | Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin | |
EA201391063A1 (en) | APOLIPOPROTEIN A-IV AS ANTIDIABETIC PEPTIDE | |
RU2009101026A (en) | APPLICATION OF THYMOSINE-ALPHA-1 FOR PRODUCING A MEDICINE FOR TREATING MALIGNANT MELANOMA IN STAGE IV | |
NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
RU2463045C1 (en) | Method of treating cerebrovascular diseases and asthenic syndrome | |
RU2009145054A (en) | HUMAN OXYNTHOMODULIN, ITS APPLICATION, A MEDICINE ON ITS BASIS AND METHOD OF APPLICATION FOR THE TREATMENT AND PREVENTION OF HYPERGLYCEMIA | |
RU2006119263A (en) | METHOD FOR TREATING PATIENTS WITH ROSATSEA | |
MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
EA200801388A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS AND DISEASES MEDIATED BY HELICOBACTER PILORY BASED ON POLYMERIC NANOPARTICLES, ITS TREATMENT METHOD AND TREATMENT METHOD | |
RU2007141393A (en) | METHOD FOR TREATING SPASTIC AND PAIN SYNDROMES IN PATIENTS WITH CONSEQUENCES OF SPIN AND SPIN INJURY | |
RU2013142835A (en) | METHOD FOR TREATING ISCHEMIC STROKE | |
EA201491841A1 (en) | COMPOSITION OF ESMOLOL FOR PARENTERAL INTRODUCTION | |
AR061046A1 (en) | MIRTAZAPINE FOR THE TREATMENT OF NEUROPATHIC PAIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant | ||
HZ9A | Changing address for correspondence with an applicant |